<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Endocrinol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Endocrinol</journal-id><journal-id journal-id-type="publisher-id">IJE</journal-id><journal-title-group><journal-title>International Journal of Endocrinology</journal-title></journal-title-group><issn pub-type="ppub">1687-8337</issn><issn pub-type="epub">1687-8345</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4935911</article-id><article-id pub-id-type="doi">10.1155/2016/9846790</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Cardiac Effects of Thyrotropin Oversuppression with Levothyroxine in Young Women with Differentiated Thyroid Cancer </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Kyung-Soon</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Son</surname><given-names>Jung-Woo</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ryu</surname><given-names>Ohk Hyun</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Moon-Gi</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Ji Yeon</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Seong Jin</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Cardiology, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon 24253, Republic of Korea</aff><aff id="I2"><sup>2</sup>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon 24253, Republic of Korea</aff><aff id="I3"><sup>3</sup>Division of Cardiology, Department of Internal Medicine, Hanil General Hospital, Seoul 01450, Republic of Korea</aff><aff id="I4"><sup>4</sup>Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang-si 14068, Republic of Korea</aff><author-notes><corresp id="cor1">*Ohk Hyun Ryu: <email>ohryu30@gmail.com</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: Thomas J. </plain></SENT>
<SENT sid="2" pm="."><plain>Fahey </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2016</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2016</year></pub-date><volume>2016</volume><elocation-id>9846790</elocation-id><history><date date-type="received"><day>8</day><month>1</month><year>2016</year></date><date date-type="rev-recd"><day>2</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016 Kyung-Soon Hong et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>Background. </plain></SENT>
<SENT sid="4" pm="."><plain>We investigated the cardiac effects of TSH (thyroid-stimulating hormone) oversuppression in women with thyroidectomized differentiated thyroid cancer (DTC) during levothyroxine suppression therapy. Methods. </plain></SENT>
<SENT sid="5" pm="."><plain>Fourteen young female patients with DTC were enrolled. </plain></SENT>
<SENT sid="6" pm="."><plain>The duration of TSH-suppressive therapy was 5 to 9 years. </plain></SENT>
<SENT sid="7" pm="."><plain>They satisfied the following criteria: (1) a serum level of TSH &lt; 0.1 mU/L in the intermediate-risk or TSH &lt; 0.3 mU/L in the low-recurrence-risk group and (2) having been receiving a fixed dose of LT4 before the study. </plain></SENT>
<SENT sid="8" pm="."><plain>Controls matched for age, sex, and body mass index (BMI) were compared in terms of the levels of serum free T4, free T3, TSH, plasma N-terminal pro-brain natriuretic peptide (NT-pro-BNP), and cardiac functions and structures. Results. </plain></SENT>
<SENT sid="9" pm="."><plain>DTC patients and control subjects were well matched in heart rate and blood pressure. </plain></SENT>
<SENT sid="10" pm="."><plain>There were marked differences in serum TSH (P = 0.001) and free T4 (P = 0.002). </plain></SENT>
<SENT sid="11" pm="."><plain>However, there were no differences between the groups in serum free T3 and plasma NT-pro-BNP. </plain></SENT>
<SENT sid="12" pm="."><plain>Furthermore, there were nonsignificant differences in cardiac functions and structures between the groups. Conclusions. </plain></SENT>
<SENT sid="13" pm="."><plain>This study shows that TSH suppression therapy in women with DTC may be safe with respect to cardiac functions and structures despite intermittent oversuppression of TSH during long-term suppressive therapy. Trial Registration. </plain></SENT>
<SENT sid="14" pm="."><plain>This trial is registered with clinicaltrials.gov identifier <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02645786?term=NCT02645786&amp;rank=1">NCT02645786</ext-link>. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="15" pm="."><plain>1. </plain></SENT>
<SENT sid="16" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain>The global incidence of thyroid cancer has been rising steadily over the recent decade [1, 2]. </plain></SENT>
<SENT sid="18" pm="."><plain>In Korea, thyroid cancer was the most common type of cancer in the 2010 cancer registry (<ext-link ext-link-type="uri" xlink:href="http://www.cancer.go.kr/upload/board/31817/179615_2.pdf">http://www.cancer.go.kr/upload/board/31817/179615_2.pdf</ext-link> accessed January 15, 2015). </plain></SENT>
<SENT sid="19" pm="."><plain>After total or near-total thyroidectomy in differentiated thyroid cancer, long-term thyrotropin (thyroid-stimulating hormone, TSH) suppression therapy with levothyroxine (LT4) should be carried out to prevent hypothyroidism and to minimize potential TSH stimulation of tumor growth in patients [3–5]. </plain></SENT>
<SENT sid="20" pm="."><plain>During long-term TSH suppression therapy, exogenous mild thyrotoxicosis or subclinical hyperthyroidism might develop and cause adverse effects on heart and bone metabolism [6, 7]. </plain></SENT>
<SENT sid="21" pm="."><plain>Several studies have reported that long-term TSH-suppressive therapy after thyroidectomy in cancer or goiter might induce increased resting heart rate, diastolic dysfunction, and increased left ventricular mass [8–10]. </plain></SENT>
<SENT sid="22" pm="."><plain>However, one study has reported that the cardiac function and structure of athyreotic thyroid cancer patients without thyrotoxic symptoms were not adversely affected despite receiving long-term TSH suppression therapy [11]. </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>The American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM (classification of malignant tumors) system has been commonly used to predict survival in differentiated thyroid cancers (DTC) [12]. </plain></SENT>
<SENT sid="24" pm="."><plain>However, the prognosis of DTC is excellent. </plain></SENT>
<SENT sid="25" pm="."><plain>Therefore, it is more important to consider the risk of recurrence and adverse effects in long-term thyroid cancer management. </plain></SENT>
<SENT sid="26" pm="."><plain>The American Thyroid Association (ATA) developed a consensus-based clinicopathologic system for the assessment of recurrence risk. </plain></SENT>
<SENT sid="27" pm="."><plain>This risk stratification system is useful when guiding TSH-suppressive therapy. </plain></SENT>
<SENT sid="28" pm="."><plain>The ATA recommends that serum TSH should be suppressed for 5 to 10 years to low concentration levels (0.1–0.5 mU/L) in high-risk but clinically and biochemically disease-free groups or to the low normal range (0.3–2.0 mU/L) in patients free of disease, especially those at low risk of recurrence, in order to best balance benefits and risks [13–15]. </plain></SENT>
<SENT sid="29" pm="."><plain>The majority of papillary thyroid cancers tend to present between the ages of 30 and 50 years (<ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/statfacts/html/thyro.html">http://seer.cancer.gov/statfacts/html/thyro.html</ext-link> accessed January 15, 2015). </plain></SENT>
<SENT sid="30" pm="."><plain>Given the same extent of disease, patients aged &lt;45 years have a distinctly better prognosis than those aged ≥45 [16]. </plain></SENT>
<SENT sid="31" pm="."><plain>In those aged less than 45, the adverse effects of long-term LT4 therapy might occur less frequently than in older age groups because they have fewer comorbid conditions. </plain></SENT>
<SENT sid="32" pm="."><plain>Most DTC patients also fall into the categories of lower intermediate risk of recurrence. </plain></SENT>
<SENT sid="33" pm="."><plain>Therefore, when deciding the target of TSH suppression for individual DTC patients, the clinician needs to take into account any underlying comorbidities and the patient's age as well as the risk of recurrence. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>When implementing chronic TSH suppression therapy with LT4, patients frequently encounter oversuppression relative to the target levels of TSH that correspond to their risk of mortality and recurrence. </plain></SENT>
<SENT sid="35" pm="."><plain>Therefore, the aim of this study was to evaluate the cardiac effects of TSH oversuppression in women with DTC during TSH-suppressive therapy for 5 to 9 years relative to their risk of recurrence. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="sec2"><title><text><SENT sid="36" pm="."><plain>2. </plain></SENT>
<SENT sid="37" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="sec2.1"><title><text><SENT sid="38" pm="."><plain>2.1. </plain></SENT>
<SENT sid="39" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="40" pm="."><plain>From chart review, we selected 96 female differentiated thyroid cancer patients who received total or near-total thyroidectomy and thereafter regularly visited the Endocrine Out-Patient Department (OPD) of Chuncheon Sacred Heart Hospital. </plain></SENT>
<SENT sid="41" pm="."><plain>The majority of papillary thyroid cancers tend to present between 30 and 50 years of age (<ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/statfacts/html/thyro.html">http://seer.cancer.gov/statfacts/html/thyro.html</ext-link> accessed January 15, 2015) and their risk of recurrence is low or intermediate. </plain></SENT>
<SENT sid="42" pm="."><plain>Menopause also might affect the cardiovascular risk factors in women. </plain></SENT>
<SENT sid="43" pm="."><plain>According to guidelines, the dose of thyroxine would be reduced after 10 years of thyroidectomy in DTC patients [13–15]. </plain></SENT>
<SENT sid="44" pm="."><plain>Therefore, additional enrollment criteria were as follows: (1) age less than 45 years when receiving total or near-total thyroidectomy, (2) serum level of TSH &lt; 0.1 mU/L in the intermediate-risk or TSH &lt; 0.3 mU/L in the low-recurrence-risk group [13, 14] over 2 years before study entry, (3) receiving TSH-suppressive therapy for 5 to 9 years with fixed dose of LT4 more than 2 years before study entry, and (4) no history of structural heart disease, arrhythmia, or cardiac symptoms (palpitation, exertional dyspnea, and chest discomfort) during therapy. </plain></SENT>
<SENT sid="45" pm="."><plain>Of the 17 patients who met the criteria, three patients did not consent to this study. </plain></SENT>
<SENT sid="46" pm="."><plain>Candidates who satisfied all the enrollment criteria took an electrocardiogram to rule out patients with arrhythmia. </plain></SENT>
<SENT sid="47" pm="."><plain>Finally, 14 DTC patients were enrolled and studied from September 2009 to March 2010. </plain></SENT>
<SENT sid="48" pm="."><plain>As each patient was enrolled, control subjects were selected from patients who visited the Endocrinology Department for thyroid nodule work-up. </plain></SENT>
<SENT sid="49" pm="."><plain>The control group had to meet the following criteria: (1) the subject matched to a patient by age (±2 years), sex, and body mass index (BMI) (±2 kg/m2), (2) levels within the reference range of serum TSH (0.3–4.6 mU/L), (3) no history of structural heart disease, arrhythmia, or cardiac symptoms, and (4) no history of comorbid diseases which affect thyroxine metabolism and cardiac structure, including hepatic or renal disease, anemia, and hypertension. </plain></SENT>
<SENT sid="50" pm="."><plain>All subjects who met the enrollment criteria took an electrocardiogram to rule out arrhythmias. </plain></SENT>
<SENT sid="51" pm="."><plain>Control subjects were recruited and tested from January 2010 to July 2011. </plain></SENT>
<SENT sid="52" pm="."><plain>The study protocol was approved by the Ethics Committee in the Chuncheon Sacred Heart Hospital (2009-19) before the study. </plain></SENT>
<SENT sid="53" pm="."><plain>All subjects provided written informed consent. </plain></SENT>
</text></p></sec><sec id="sec2.2"><title><text><SENT sid="54" pm="."><plain>2.2. </plain></SENT>
<SENT sid="55" pm="."><plain>Assays </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>On the examination day, all participants were prohibited from smoking and consuming caffeine. </plain></SENT>
<SENT sid="57" pm="."><plain>After a light breakfast and medication, including LT4 in cancer patients, participants visited the hospital before 9 AM. </plain></SENT>
<SENT sid="58" pm="."><plain>We investigated the comorbid conditions of the participants. </plain></SENT>
<SENT sid="59" pm="."><plain>Body weight and height were measured while the subjects wore light clothing without shoes. </plain></SENT>
<SENT sid="60" pm="."><plain>The body mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared. </plain></SENT>
<SENT sid="61" pm="."><plain>Their blood pressure was taken after a 10-minute rest period. </plain></SENT>
<SENT sid="62" pm="."><plain>Subsequently, each subject underwent a 2-dimensional echocardiogram carried out by one examiner. </plain></SENT>
<SENT sid="63" pm="."><plain>After the cardiac work-up, blood samples were drawn for test of thyroid function. </plain></SENT>
<SENT sid="64" pm="."><plain>Blood samples were collected in prechilled tubes containing EDTA, immediately placed on ice, and promptly centrifuged at 4°C. </plain></SENT>
<SENT sid="65" pm="."><plain>After separation, plasma was stored at −80°C for the N-terminal pro-brain natriuretic peptide (NT-pro-BNP). </plain></SENT>
</text></p><p><text><SENT sid="66" pm="."><plain>Serum thyroid function tests were performed by a chemiluminescent immunoassay (UNICELL DXI800, Beckman Coulter, USA). </plain></SENT>
<SENT sid="67" pm="."><plain>Serum TSH (reference value: 0.3–4.6 mU/L, detection limit: 0.0025 mU/L), free T4 (reference value: 7.0–20.0 pmol/L), and free T3 (reference value: 4.0–5.9 pmol/L) were measured. </plain></SENT>
<SENT sid="68" pm="."><plain>Plasma NT-pro-BNP measurements were done using chemiluminescent immunoassay method (Roche E170, Roche Diagnostics, Germany). </plain></SENT>
</text></p></sec><sec id="sec2.3"><title><text><SENT sid="69" pm="."><plain>2.3. </plain></SENT>
<SENT sid="70" pm="."><plain>Echocardiography </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>Comprehensive transthoracic echocardiography was performed using commercially available equipment (IE33, Philips Medical System, Andover, Massachusetts). </plain></SENT>
<SENT sid="72" pm="."><plain>Standard 2-dimensional measurements were obtained as recommended by the American Society of Echocardiography (ASE) in the left lateral position [17]. </plain></SENT>
<SENT sid="73" pm="."><plain>Left atrial volume index was measured by the biplane area-length method. </plain></SENT>
<SENT sid="74" pm="."><plain>Left ventricular (LV) mass was calculated using the following equation: LV mass = 0.8(1.04{[LVIDd + PWTd + IVSd]3 − [LVIDd]3}) + 0.6, where LVID is LV end-diastolic dimension, PWT is posterior wall thickness, IVS is interventricular septal wall thickness, and d is diastole. </plain></SENT>
<SENT sid="75" pm="."><plain>Systolic function was evaluated by measurements of left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) of the LV. </plain></SENT>
<SENT sid="76" pm="."><plain>The following parameters of diastolic function were measured by tissue Doppler-derived imaging: early diastolic flow of mitral valve velocity (E), late diastolic flow of mitral valve velocity (A), early diastolic mitral annular velocity (e′), late diastolic mitral annular velocity (a′), and isovolumetric relaxation time (IVRT) were measured from the septal corner of the mitral annulus in the apical 4-chamber view. </plain></SENT>
<SENT sid="77" pm="."><plain>To evaluate the GLS of the left ventricle, echocardiographic images were obtained at the apical 4-chamber view and the strain was analyzed based on routine DICOM (Digital Imaging and Communications in Medicine) data sets using software (2D Cardiac Performance Analysis, TomTec, Munich, Germany). </plain></SENT>
<SENT sid="78" pm="."><plain>A region of interest was manually placed on the endocardial and epicardial borders. </plain></SENT>
<SENT sid="79" pm="."><plain>The echocardiographic data were gathered and analyzed by 2 experienced echocardiographers who were unaware of any corresponding clinical data. </plain></SENT>
</text></p></sec><sec id="sec2.4"><title><text><SENT sid="80" pm="."><plain>2.4. </plain></SENT>
<SENT sid="81" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="82" pm="."><plain>Data were reported as means and standard deviation (SD). </plain></SENT>
<SENT sid="83" pm="."><plain>For the comparison of means between groups, we used the Mann-Whitney test because the sample size was small (n = 14 for each group). </plain></SENT>
<SENT sid="84" pm="."><plain>All P values calculated are two-tailed and considered significant at P &lt; 0.05. </plain></SENT>
<SENT sid="85" pm="."><plain>All statistical analysis was performed using SPSS 20.0 software (SPSS Inc., Chicago, USA). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec id="sec3"><title><text><SENT sid="86" pm="."><plain>3. </plain></SENT>
<SENT sid="87" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="88" pm="."><plain>All cancer patients were of stage 1 in the AJCC staging system. </plain></SENT>
<SENT sid="89" pm="."><plain>10 patients were classified as having intermediate risk and 4 patients fell into the low-risk-of-recurrence category. </plain></SENT>
<SENT sid="90" pm="."><plain>The mean LT4 dose was 2.77 μg/kg (ranging from 1.67 to 3.82 μg/kg). </plain></SENT>
<SENT sid="91" pm="."><plain>The baseline characteristics of cancer patients are summarized in Table 1. </plain></SENT>
<SENT sid="92" pm="."><plain>While the cancer patients and control groups were well matched in age, BMI, heart rate, and blood pressure, there were marked differences in serum TSH (P = 0.001) and free T4 (P = 0.002). </plain></SENT>
<SENT sid="93" pm="."><plain>However, there were no differences between groups in the mean quantities of serum free T3 and plasma NT-pro-BNP (Table 2). </plain></SENT>
<SENT sid="94" pm="."><plain>There were no significant differences in 2D echocardiographic parameters compared with the control group. </plain></SENT>
<SENT sid="95" pm="."><plain>The LV chamber size and LV systolic function (LVEF and GLS) had no differences. </plain></SENT>
<SENT sid="96" pm="."><plain>The LV mass index was higher than in the control group, but not significantly (87.6 g/m2 versus 79.3 g/m2, P = 0.134). </plain></SENT>
<SENT sid="97" pm="."><plain>There were no significant differences in diastolic echocardiographic parameters, such as E, A, e′, a′, IVRT, and E/e′. </plain></SENT>
<SENT sid="98" pm="."><plain>The GLS of the left ventricle was also not different between the groups (Table 3). </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec id="sec4"><title><text><SENT sid="99" pm="."><plain>4. </plain></SENT>
<SENT sid="100" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="101" pm="."><plain>The principal finding of the present study was that TSH oversuppression therapy may be safe in asymptomatic athyreotic young women with DTC (intermediate or low risk of recurrence) during less-than-10-year TSH-suppressive therapy. </plain></SENT>
</text></p><sec id="sec4.1"><title><text><SENT sid="102" pm="."><plain>4.1. </plain></SENT>
<SENT sid="103" pm="."><plain>Cardiac Dysfunction in Thyrotoxicosis </plain></SENT>
</text></title><p><text><SENT sid="104" pm="."><plain>Thyrotoxicosis can influence cardiac function and structure and clinical symptoms [18]. </plain></SENT>
<SENT sid="105" pm="."><plain>Tetraiodothyronine (T4) is biologically inactive in target tissues until converted to triiodothyronine (T3). </plain></SENT>
<SENT sid="106" pm="."><plain>About 80% of circulating T3 comes from the deiodination of T4 in peripheral tissues [19]. </plain></SENT>
<SENT sid="107" pm="."><plain>Thyroid hormone, especially T3, causes the gene expression of cardiac contractile proteins and channels or transporters related to ion flux, including calcium, by binding to nuclear T3 receptors or directly affects ion transport in a receptor-independent manner in cardiac myocytes [20]. </plain></SENT>
<SENT sid="108" pm="."><plain>Changes in T3 status mainly influence cardiac action involving cardiac contractility, electrophysiological function, and cardiac structure. </plain></SENT>
<SENT sid="109" pm="."><plain>Hyperthyroidism, such as Graves's disease and nodular thyroid disease, is characterized biochemically by a low TSH level and elevated T4, T3, or both. </plain></SENT>
<SENT sid="110" pm="."><plain>Therefore, hyperthyroidism increases cardiac contractility, resting heart rate, tachyarrhythmias, and LV muscle mass and eventually has consequences ranging from diastolic dysfunction to heart failure and atrial fibrillation [18, 21–23]. </plain></SENT>
<SENT sid="111" pm="."><plain>However, our result shows that cardiac function and structure displayed no significant differences, in women with DTC and thyrotoxicosis caused by thyroxine, compared with a normal control group. </plain></SENT>
<SENT sid="112" pm="."><plain>When receiving long-term TSH suppression therapy with LT4 based on the TNM stage and risk of recurrence of DTC, patients frequently encounter exogenous subclinical hyperthyroidism or a variable degree of thyrotoxicosis. </plain></SENT>
<SENT sid="113" pm="."><plain>Traditionally, T3 levels in exogenous thyrotoxicosis were normally maintained by standard LT4 therapy without the inclusion of T3 in patients who had undergone near-total or total thyroidectomy [24]. </plain></SENT>
<SENT sid="114" pm="."><plain>In this study, the levels of serum FT4 were elevated and levels of TSH were suppressed compared to those in controls. </plain></SENT>
<SENT sid="115" pm="."><plain>However, there were no differences in the levels of serum FT3 between the cancer and control groups. </plain></SENT>
<SENT sid="116" pm="."><plain>Peripheral autoregulation of T4-to-T3 conversion appears to be operative at both ends of the T4 spectrum and may serve to maintain or protect serum T3 levels [25]. </plain></SENT>
<SENT sid="117" pm="."><plain>Endogenous hyperthyroidism increases thyroid hormone production (T4 and T3) and the fraction of T3 relative to T4 in thyroid secretion by the increased activity of type 1 and 2 iodothyronine deiodinase. </plain></SENT>
<SENT sid="118" pm="."><plain>Although mild thyrotoxicosis had been developed in DTC patients in this study, no significantly different cardiac effects were caused by the normal levels of T3 due to the peripheral autoregulation of T4-to-T3 conversion. </plain></SENT>
<SENT sid="119" pm="."><plain>Several studies have been published investigating cardiac effects in athyreotic patients with exogenous subclinical hyperthyroidism. </plain></SENT>
<SENT sid="120" pm="."><plain>Biondi et al. show that long-term levothyroxine therapy was associated with significantly higher LV mass index, increased heart rate, and significantly impaired cardiac reserve and exercise capacity compared to controls. </plain></SENT>
<SENT sid="121" pm="."><plain>These studies, however, were performed in symptomatic patients (60~100%) and in a heterogeneous group (multinodular goiter and DTC) while all our patients were asymptomatic and formed a homogenous group (women ≤ 45 years with DTC) [8, 9, 26]. </plain></SENT>
<SENT sid="122" pm="."><plain>Shapiro et al. have shown that patients with minimal symptoms by a score questionnaire had minimal cardiac effects and suggested that if there are no thyrotoxic symptoms during TSH-suppressive therapy, it is not necessary to perform additional cardiac evaluation in DTC patients [11]. </plain></SENT>
<SENT sid="123" pm="."><plain>Fazio et al. have reported that TSH-suppressive therapy with levothyroxine in DTC patients increases LV mass and causes diastolic dysfunction. </plain></SENT>
<SENT sid="124" pm="."><plain>However, the DTC patients in that study had a TSH level of less than 0.05 mU/L, while our patients had a serum level of TSH &lt; 0.1 mU/L in the intermediate-risk-of-recurrence group and &lt;0.3 mU/L in the lower-risk-of-recurrence group [27]. </plain></SENT>
<SENT sid="125" pm="."><plain>Also, the calculation formula of LV mass was different in the above studies (Penn or Devereux), compared with our formula (ASE), which is now widely used. </plain></SENT>
<SENT sid="126" pm="."><plain>We also analyze the GLS of the LV, as it is known that higher GLS predicts a poor prognosis for decreased LV systolic function, heart failure, and ischemic cardiomyopathy, and we show no significant difference between the TSH suppression group and control subjects [28–30]. </plain></SENT>
<SENT sid="127" pm="."><plain>This study had several strengths. </plain></SENT>
<SENT sid="128" pm="."><plain>The athyreotic patients were exclusively DTC patients with low or intermediate risk of recurrence and were all women aged less than 45 years (the most prevalent group in DTC) when they received a total or near-total thyroidectomy. </plain></SENT>
<SENT sid="129" pm="."><plain>The serum TSH levels were oversuppressed for more than 2 years with LT4 relative to the target levels of TSH that corresponds to their risk of mortality and recurrence based on management guidelines. </plain></SENT>
<SENT sid="130" pm="."><plain>These enrollment criteria suggest that the oversuppression of TSH frequently encountered during the long-term management of young DTC patients (&lt;45 years old) without heart diseases may be safe for cardiac function and structure, especially for patients with the low or intermediate risk of recurrence. </plain></SENT>
<SENT sid="131" pm="."><plain>However, this study had some limitations. </plain></SENT>
<SENT sid="132" pm="."><plain>First, the small number of patients in this study might increase the possibility of beta error (false-negative), which means the failure to detect cardiac effect by TSH oversuppression that is present. </plain></SENT>
<SENT sid="133" pm="."><plain>A subgroup analysis according to the risk of recurrence and extent of thyroidectomy was not possible. </plain></SENT>
<SENT sid="134" pm="."><plain>Second, blood samples were collected following the ingestion of LT4 by DTC patients. </plain></SENT>
<SENT sid="135" pm="."><plain>The serum free T4 levels in DTC patients measured in such a way might be elevated compared to if they were measured prior to ingestion of LT4 [31]. </plain></SENT>
<SENT sid="136" pm="."><plain>The timing of blood sampling might increase the difference of serum free T4 concentrations between groups. </plain></SENT>
<SENT sid="137" pm="."><plain>Third, we did not check the thyrotoxic symptom score by standardized questionnaires [32]. </plain></SENT>
<SENT sid="138" pm="."><plain>Fourth, some of the enrolled DTC patients had comorbid diseases, such as hypertension and anemia, which might affect cardiac structure and function. </plain></SENT>
<SENT sid="139" pm="."><plain>The control subject was matched to a patient by age, sex, and BMI. </plain></SENT>
<SENT sid="140" pm="."><plain>We could not match the comorbid diseases exactly between groups. </plain></SENT>
<SENT sid="141" pm="."><plain>This prevented a direct comparison with other previous studies [8–11]. </plain></SENT>
<SENT sid="142" pm="."><plain>Fifth, the most current ATA guidelines for diagnosis and management of DTC patients have just been released and direct physicians to adjust TSH suppression based upon ongoing risk stratification and response to therapy making this report less applicable [33]. </plain></SENT>
</text></p><p><text><SENT sid="143" pm="."><plain>In conclusion, the present study shows that TSH-suppressive therapy with LT4 in asymptomatic athyreotic women with DTC, especially in the low- or intermediate-risk-of-recurrence categories, may be safe for cardiac function and structure despite intermittent oversuppression during long-term (less than 10 years) TSH-suppressive therapy. </plain></SENT>
<SENT sid="144" pm="."><plain>Also, this study suggests that if no cardiac symptoms are present in overly suppressed DTC patients, additional cardiac evaluation for cardiac function and structure is not necessary. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="145" pm="."><plain>The authors gratefully acknowledge Eun-Ei Gang and Deok-KiYoun for their technical support and coordination in this study. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec><title>Competing Interests</title><p>The authors declare that there are no competing interests regarding the publication of this paper.</p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="146" pm="."><plain>1ChenA. </plain></SENT>
<SENT sid="147" pm="."><plain>Y.JemalA.WardE. </plain></SENT>
<SENT sid="148" pm="."><plain>M.Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005Cancer2009115163801380710.1002/cncr.244162-s2.0-6854909987919598221 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="149" pm="."><plain>2KilfoyB. </plain></SENT>
<SENT sid="150" pm="."><plain>A.ZhengT.HolfordT. </plain></SENT>
<SENT sid="151" pm="."><plain>R.International patterns and trends in thyroid cancer incidence, 1973–2002Cancer Causes and Control200920552553110.1007/s10552-008-9260-42-s2.0-6664911235519016336 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="152" pm="."><plain>3CooperD. </plain></SENT>
<SENT sid="153" pm="."><plain>S.SpeckerB.HoM.Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative RegistryThyroid19988973774410.1089/thy.1998.8.7372-s2.0-131442617469777742 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="154" pm="."><plain>4McGriffN. </plain></SENT>
<SENT sid="155" pm="."><plain>J.CsakoG.GourgiotisL.GuthrieL. </plain></SENT>
<SENT sid="156" pm="."><plain>C.PucinoF.SarlisN. </plain></SENT>
<SENT sid="157" pm="."><plain>J.Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancerAnnals of Medicine2002347-855456410.1080/0785389023211177602-s2.0-003695796612553495 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="158" pm="."><plain>5BrabantG.Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets?The Journal of Clinical Endocrinology &amp; Metabolism20089341167116910.1210/jc.2007-22282-s2.0-4204912029118390811 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="159" pm="."><plain>6SugitaniI.FujimotoY.Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled studySurgery201115061250125710.1016/j.surg.2011.09.0132-s2.0-8275516456022136848 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="160" pm="."><plain>7AbonowaraA.QuraishiA.SappJ. </plain></SENT>
<SENT sid="161" pm="."><plain>L.Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancerClinical and Investigative Medicine2012353E152E1562-s2.0-8486541519822673318 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="162" pm="."><plain>8BiondiB.FazioS.CarellaC.Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxineJournal of Clinical Endocrinology and Metabolism19937723343382-s2.0-00273271398345037 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="163" pm="."><plain>9BiondiB.FazioS.CuocoloA.Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxineThe Journal of Clinical Endocrinology &amp; Metabolism199681124224422810.1210/jc.81.12.42242-s2.0-00298023338954019 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="164" pm="."><plain>10MercuroG.PanzutoM. </plain></SENT>
<SENT sid="165" pm="."><plain>G.BinaA.Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoringJournal of Clinical Endocrinology and Metabolism200085115916410.1210/jc.85.1.1592-s2.0-003445638110634380 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="166" pm="."><plain>11ShapiroL. </plain></SENT>
<SENT sid="167" pm="."><plain>E.SievertR.OngL.Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxineJournal of Clinical Endocrinology and Metabolism19978282592259510.1210/jc.82.8.25922-s2.0-00308529049253339 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="168" pm="."><plain>12WadaN.NakayamaH.SuganumaN.Prognostic value of the sixth edition AJCC/UICC TNM classification for differentiated thyroid carcinoma with extrathyroid extensionJournal of Clinical Endocrinology and Metabolism200792121521810.1210/jc.2006-14432-s2.0-3384610841217077130 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="169" pm="."><plain>13CooperD. </plain></SENT>
<SENT sid="170" pm="."><plain>S.DohertyG. </plain></SENT>
<SENT sid="171" pm="."><plain>M.HaugenB. </plain></SENT>
<SENT sid="172" pm="."><plain>R.Management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid200616210914110.1089/thy.2006.16.1092-s2.0-3364546571916420177 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="173" pm="."><plain>14CooperD. </plain></SENT>
<SENT sid="174" pm="."><plain>S.DohertyG. </plain></SENT>
<SENT sid="175" pm="."><plain>M.HaugenB. </plain></SENT>
<SENT sid="176" pm="."><plain>R.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid200919111167121410.1089/thy.2009.011019860577 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="177" pm="."><plain>15TuttleR. </plain></SENT>
<SENT sid="178" pm="."><plain>M.TalaH.ShahJ.Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging systemThyroid201020121341134910.1089/thy.2010.01782-s2.0-7864970149221034228 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="179" pm="."><plain>16VerburgF. </plain></SENT>
<SENT sid="180" pm="."><plain>A.MäderU.TanaseK.Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patientsJournal of Clinical Endocrinology and Metabolism201398117218010.1210/jc.2012-24582-s2.0-8487206099623150687 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="181" pm="."><plain>17LangR. </plain></SENT>
<SENT sid="182" pm="."><plain>M.BierigM.DevereuxR. </plain></SENT>
<SENT sid="183" pm="."><plain>B.Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of CardiologyJournal of American Society of Echocardiography200518121440146310.1016/j.echo.2005.10.005 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="184" pm="."><plain>18KleinI.OjamaaK.Thyroid hormone and the cardiovascular systemThe New England Journal of Medicine2001344750150910.1056/nejm2001021534407072-s2.0-003586497511172193 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="185" pm="."><plain>19LarsenP. </plain></SENT>
<SENT sid="186" pm="."><plain>R.SilvaJ. </plain></SENT>
<SENT sid="187" pm="."><plain>E.KaplanM. </plain></SENT>
<SENT sid="188" pm="."><plain>M.Relationships between circulating and intracellular thyroid hormones: physiological and clinical implicationsEndocrine Reviews1981218710210.1210/edrv-2-1-872-s2.0-00197549496271545 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="189" pm="."><plain>20KahalyG. </plain></SENT>
<SENT sid="190" pm="."><plain>J.DillmannW. </plain></SENT>
<SENT sid="191" pm="."><plain>H.Thyroid hormone action in the heartEndocrine Reviews200526570472810.1210/er.2003-00332-s2.0-2374444579615632316 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="192" pm="."><plain>21KleinI.OjamaaK.Thyrotoxicosis and the heartEndocrinology and Metabolism Clinics of North America1998271516210.1016/s0889-8529(05)70297-82-s2.0-00318962179534027 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="193" pm="."><plain>22BiondiB.Mechanisms in endocrinology: heart failure and thyroid dysfunctionEuropean Journal of Endocrinology2012167560961810.1530/eje-12-06272-s2.0-8486749173822956554 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="194" pm="."><plain>23WeltmanN. </plain></SENT>
<SENT sid="195" pm="."><plain>Y.WangD.RedetzkeR. </plain></SENT>
<SENT sid="196" pm="."><plain>A.GerdesA. </plain></SENT>
<SENT sid="197" pm="."><plain>M.Longstanding hyperthyroidism is associated with normal or enhanced intrinsic cardiomyocyte function despite decline in global cardiac functionPLoS ONE2012710e4665510.1371/journal.pone.00466552-s2.0-84867135272 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="198" pm="."><plain>24JonklaasJ.DavidsonB.BhagatS.SoldinS. </plain></SENT>
<SENT sid="199" pm="."><plain>J.Triiodothyronine levels in athyreotic individuals during levothyroxine therapyThe Journal of the American Medical Association2008299776977710.1001/jama.299.7.7692-s2.0-3954909730118285588 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="200" pm="."><plain>25KeckF. </plain></SENT>
<SENT sid="201" pm="."><plain>S.LoosU.Peripheral autoregulation of thyromimetic activity in manHormone and Metabolic Research198820211011410.1055/s-2007-10107652-s2.0-00238872983371862 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="202" pm="."><plain>26BiondiB.FazioS.CarellaC.Control of adrenergic overactivity by β-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxineJournal of Clinical Endocrinology and Metabolism19947851028103310.1210/jc.78.5.10282-s2.0-00282966178175955 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="203" pm="."><plain>27FazioS.BiondiB.CarellaC.Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of β-blockadeThe Journal of Clinical Endocrinology &amp; Metabolism1995807222222262-s2.0-00290024157608283 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="204" pm="."><plain>28MignotA.DonalE.ZarouiA.Global longitudinal strain as a major predictor of cardiac events in patients with depressed left ventricular function: a multicenter studyJournal of the American Society of Echocardiography201023101019102410.1016/j.echo.2010.07.0192-s2.0-7795722553720810243 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="205" pm="."><plain>29BertiniM.NgA. </plain></SENT>
<SENT sid="206" pm="."><plain>C. </plain></SENT>
<SENT sid="207" pm="."><plain>T.AntoniM. </plain></SENT>
<SENT sid="208" pm="."><plain>L.Global longitudinal strain predicts long-term survival in patients with chronic ischemic cardiomyopathyCirculation: Cardiovascular Imaging20125338339110.1161/CIRCIMAGING.111.9704342-s2.0-8486368670422412068 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="209" pm="."><plain>30IacovielloM.PuzzovivoA.GuidaP.Independent role of left ventricular global longitudinal strain in predicting prognosis of chronic heart failure patientsEchocardiography201330780381110.1111/echo.121422-s2.0-8488092322223488596 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="210" pm="."><plain>31SymonsR. </plain></SENT>
<SENT sid="211" pm="."><plain>G.MurphyL. </plain></SENT>
<SENT sid="212" pm="."><plain>J.Acute changes in thyroid function tests following ingestion of thyroxineClinical Endocrinology198319453954610.1111/j.1365-2265.1983.tb00029.x2-s2.0-00206271346627702 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="213" pm="."><plain>32KleinI.TrzepaczP. </plain></SENT>
<SENT sid="214" pm="."><plain>T.RobertsM.LeveyG. </plain></SENT>
<SENT sid="215" pm="."><plain>S.Symptom rating scale for assessing hyperthyroidismArchives of Internal Medicine1988148238739010.1001/archinte.1988.003800201310182-s2.0-00238453683124776 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="216" pm="."><plain>33HaugenB. </plain></SENT>
<SENT sid="217" pm="."><plain>R.AlexanderE. </plain></SENT>
<SENT sid="218" pm="."><plain>K.BibleK. </plain></SENT>
<SENT sid="219" pm="."><plain>C.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid201526113326462967 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="220" pm="."><plain>Baseline characteristics of differentiated thyroid cancer patients based on TNM classification and recurrence-risk stratification system. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>Age </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>Thyroidectomy </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>Cell type </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>Remnantablation </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>TNMsystem </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>Recurrence risk </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>LT4dose(μg/kg) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>TSHsuppression(year) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>Comorbidity(ongoing medication) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>49 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>Total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>T4aN0M0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>3.34 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>CML (imatinib) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>36 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>Total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>No </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>T2N1aM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>2.20 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>54 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Near-total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>T1bN0M0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>Low </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>2.78 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>PMS (HT) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>48 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>No </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>T2N1aM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>2.55 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>HTN (CCB) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>33 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>Near-total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>Hurthle </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>T1bN1aM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>2.66 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>38 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>Near-total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>T3N1bM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>2.80 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>38 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>Total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>T2N0M0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>Low </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>2.79 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>50 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>Near-total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>T2N1aM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>3.05 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>41 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>Near-total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>T1aN1aM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>2.28 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>32 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>Total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>T2N0M0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>Low </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>2.44 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>38 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>Total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>T2N1aM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>3.82 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>45 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>Total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>Mixed </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>T2N0M0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>Low </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>1.67 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>None </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>51 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>Near-total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>T2N1aM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>2.79 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>IDA (iron) </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>48 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>Total </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>Papillary </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>Yes </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>T1bN1aM0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>Intermediate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>3.62 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>PTB </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>CCB, calcium channel blocker; CML, chronic myeloid leukemia; HT, hormonal therapy; HTN, hypertension; IDA, iron deficiency anemia; LT4, levothyroxine; PMS, postmenopausal syndrome; PTB, pulmonary tuberculosis; TSH, thyroid-stimulating hormone.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="356" pm="."><plain>Clinical and laboratory characteristics of the control group and differentiated thyroid cancer patients receiving long-term (5 to 9 years) levothyroxine suppression therapy. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>Parameters </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>Cancer group (n = 14) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>Control patients (n = 14) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>P value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain> 42.9 ± 7.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain> 42.9 ± 6.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>0.637 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>BMI (kg/m2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain> 23.1 ± 2.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain> 23.5 ± 1.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>0.198 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>Heart rate (beats/min) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain> 68.0 ± 9.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain> 66.1 ± 8.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>0.484 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>SBP (mmHg) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain> 116.4 ± 10.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain> 118.6 ± 12.9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>0.662 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>DBP (mmHg) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain> 75.7 ± 6.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain> 76.4 ± 9.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>0.819 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>TSH (mU/L) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain> 0.06 ± 0.03 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain> 1.58 ± 1.29 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>Free T4 (pmol/L) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain> 19.7 ± 5.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain> 11.5 ± 2.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>0.002 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>Free T3 (pmol/L) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain> 4.4 ± 0.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain> 4.3 ± 0.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>0.730 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>NT-pro-BNP (pg/mL) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain> 59.2 ± 50.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain> 38.0 ± 19.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>0.198 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean ± standard deviation. <italic>P</italic> values are calculated by Mann-Whitney test. BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; TSH, thyroid-stimulating hormone.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p><text><SENT sid="397" pm="."><plain>Echocardiographic parameters in differentiated thyroid cancer patients and the control group. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>Parameters </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>Cancer group (n = 14) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>Control group (n = 14) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>P value </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>LVEDD (mm) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain> 48.6 ± 4.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain> 48.8 ± 2.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>0.667 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>LVESD (mm) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain> 30.1 ± 2.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain> 30 ± 4.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>0.982 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>LV mass index (g/m2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain> 87.6 ± 20.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain> 79.3 ± 11.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>0.134 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>LAVi (mL/m2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain> 26.9 ± 7.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain> 31.4 ± 7.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>0.178 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>LVEF (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain> 67.8 ± 4.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain> 68.1 ± 7.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>0.701 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>E velocity (cm/s) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain> 85.1 ± 16.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain> 79.7 ± 15.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>0.352 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>A velocity (cm/s) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain> 62.8 ± 14.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain> 68.3 ± 18.2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>0.454 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>e′ velocity (cm/s) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain> 9.2 ± 1.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain> 8.5 ± 1.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>0.239 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>a′ velocity (cm/s) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain> 8.1 ± 1.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain> 7.9 ± 1.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>0.616 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>IVRT (millisecond) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain> 94.1 ± 7.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain> 92.4 ± 4.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>0.832 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>E/e′ ratio </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain> 9.6 ± 2.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain> 9.6 ± 2.1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>0.756 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>GLS (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain> −21.6 ± 2.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain> −21.2 ± 2.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>0.804 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean ± standard deviation. <italic>P</italic> values are calculated by Mann-Whitney test. <italic>A</italic>, late diastolic flow of mitral valve; <italic>a</italic>′, late diastolic motion of mitral annulus; <italic>E</italic>, early diastolic flow of mitral valve; <italic>e</italic>′, early diastolic motion of mitral annulus; IVRT, isovolumetric relaxation time; GLS, global longitudinal strain; LAVi, left atrial volume index; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
